Mesoblast Stock Analysis

MESO Stock  USD 15.62  3.28  26.58%   
Mesoblast is undervalued with Real Value of 18.13 and Target Price of 27.0. The main objective of Mesoblast stock analysis is to determine its intrinsic value, which is an estimate of what Mesoblast is worth, separate from its market price. There are two main types of Mesoblast's stock analysis: fundamental analysis and technical analysis.
The Mesoblast stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Mesoblast is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Mesoblast Stock trading window is adjusted to America/New York timezone.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Mesoblast Stock Analysis Notes

The book value of the company was now reported as 0.4. The company recorded a loss per share of 1.28. Mesoblast had not issued any dividends in recent years. The entity had 1:2 split on the 10th of January 2024. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mesoblast contact FACP FACRA at 61 3 9639 6036 or learn more at https://www.mesoblast.com.

Mesoblast Quarterly Total Revenue

1.58 Million

Mesoblast Investment Alerts

Mesoblast is way too risky over 90 days horizon
Mesoblast appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (87.96 M) with loss before overhead, payroll, taxes, and interest of (20.99 M).
Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Mesoblast has a poor financial position based on the latest SEC disclosures
Latest headline from gurufocus.com: Jefferies Adjusts Mesoblast Rating and Price Target Post Q4 Report MESO Stock News

Mesoblast Upcoming and Recent Events

Earnings reports are used by Mesoblast to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
26th of February 2024
Upcoming Quarterly Report
View
23rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

Mesoblast Largest EPS Surprises

Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-02-27
2022-12-31-0.1802-0.15740.022812 
2022-05-31
2022-03-31-0.13-0.16-0.0323 
2020-05-27
2020-03-31-0.17-0.140.0317 
View All Earnings Estimates

Mesoblast Environmental, Social, and Governance (ESG) Scores

Mesoblast's ESG score is a quantitative measure that evaluates Mesoblast's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Mesoblast's operations that may have significant financial implications and affect Mesoblast's stock price as well as guide investors towards more socially responsible investments.

Mesoblast Thematic Classifications

In addition to having Mesoblast stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Mesoblast Stock Institutional Investors

Shares
Marshall Wace Asset Management Ltd2025-03-31
71.7 K
Rockbridge Investment Management, Llc2025-03-31
49.1 K
Prosperity Wealth Management Inc2025-03-31
48.7 K
Jane Street Group Llc2025-03-31
48.6 K
Oasis Management Co. Ltd2025-03-31
41.5 K
Lpl Financial Corp2025-03-31
40 K
Bank Of America Corp2025-03-31
36.6 K
Xy Capital Ltd2025-03-31
27.8 K
Wells Fargo & Co2025-03-31
26.6 K
Blackrock Inc2025-03-31
714.9 K
Morgan Stanley - Brokerage Accounts2025-03-31
544.6 K
Note, although Mesoblast's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mesoblast Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2 B.

Management Efficiency

Mesoblast has return on total asset (ROA) of (0.0485) % which means that it has lost $0.0485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2131) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities.
Leadership at Mesoblast emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Operating Margin
(6.33)
Beta
1.418
Return On Assets
(0.05)
Return On Equity
(0.21)

Technical Drivers

As of the 20th of July, Mesoblast secures the Mean Deviation of 3.51, downside deviation of 4.12, and Risk Adjusted Performance of 0.1324. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them.

Mesoblast Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Mesoblast for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Mesoblast short-term fluctuations and highlight longer-term trends or cycles.

Mesoblast Outstanding Bonds

Mesoblast issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mesoblast uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mesoblast bonds can be classified according to their maturity, which is the date when Mesoblast has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Mesoblast Predictive Daily Indicators

Mesoblast intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mesoblast stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Mesoblast Corporate Filings

6K
18th of July 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
15th of July 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
1st of July 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
12th of June 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
15th of May 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
30th of April 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
29th of April 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
24th of April 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify

Mesoblast Forecast Models

Mesoblast's time-series forecasting models are one of many Mesoblast's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mesoblast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Mesoblast Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mesoblast prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mesoblast shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mesoblast. By using and applying Mesoblast Stock analysis, traders can create a robust methodology for identifying Mesoblast entry and exit points for their positions.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.

Current Mesoblast Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mesoblast analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mesoblast analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
27.0Strong Buy3Odds
Mesoblast current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Mesoblast analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mesoblast stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mesoblast, talking to its executives and customers, or listening to Mesoblast conference calls.
Mesoblast Analyst Advice Details

Mesoblast Stock Analysis Indicators

Mesoblast stock analysis indicators help investors evaluate how Mesoblast stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mesoblast shares will generate the highest return on investment. By understating and applying Mesoblast stock analysis, traders can identify Mesoblast position entry and exit signals to maximize returns.
Begin Period Cash Flow71.3 M
Long Term Debt100.5 M
Common Stock Shares Outstanding98.7 M
Total Stockholder Equity480.4 M
Total Cashflows From Investing Activities-97 K
Tax Provision-191 K
Property Plant And Equipment Net3.8 M
Cash And Short Term Investments62.6 M
Cash62.6 M
Accounts Payable7.1 M
Net Debt56.4 M
50 Day M A11.2246
Total Current Liabilities73.2 M
Other Operating Expenses90 M
Non Current Assets Total582.7 M
Forward Price Earnings454.5455
Non Currrent Assets Other2.1 M
Stock Based Compensation5.9 M
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.28)
Revenue Per Share
0.05
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.05)
Return On Equity
(0.21)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.